Streetbeat News

Regulatory

DRMA

NCNA

RFL

XCUR

Exicure, Inc. (NASDAQ:XCUR) shares surged over 49% in pre-market trading after the company entered into debt-for-equity exchange agreements and regained Nasdaq compliance. Other notable pre-market movers include NuCana plc (NASDAQ:NCNA) with a 94.4% gain due to positive Phase 2 study data, and Dermata Therapeutics, Inc. (NASDAQ:DRMA) rising 73.4%. On the downside, Rafael Holdings, Inc. (NYSE:RFL) fell 40.1% after previous gains.

Portfolio Pulse from Avi Kapoor

September 16, 2024 | 10:07 am

TIL

Instil Bio has announced a global registrational strategy for its PD-L1xVEGF bispecific antibody, SYN-2510/IMM2510, in combination with chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). The company plans to initiate Phase 1b/2 trials in China in late 2024 for NSCLC and early 2025 for TNBC. A US IND submission for SYN-2510 is targeted for late 2024, with a Phase 2 trial for second-line NSCLC.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 10:02 am

ME

23andMe presented nonclinical data at the ESMO Congress showing the anti-tumor activity of its 23ME-01473 antibody, which targets the NKG2D ligand ULBP6. The antibody inhibited tumor growth in a mouse model of non-small cell lung cancer. Elevated ULBP6 levels were confirmed in certain carcinomas, suggesting potential clinical applications. A Phase 1 trial is ongoing, with the first patient dosed in March 2024.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 9:27 am

INCY

Incyte announced successful results from its Phase 3 trial of retifanlimab combined with chemotherapy for treating squamous cell anal carcinoma. The trial met its primary endpoint, supporting a planned U.S. filing for a supplemental Biologics License Application by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 9:23 am

NUVB

Nuvation Bio announced promising pooled data from TRUST-I and TRUST-II studies for taletrectinib, showing significant tumor shrinkage in advanced ROS1-positive NSCLC patients. The drug demonstrated durable responses, prolonged progression-free survival, and a favorable safety profile. Nuvation Bio plans to submit a New Drug Application to the FDA in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:51 am

ACRV

Acrivon Therapeutics reported promising Phase 2 data for ACR-368 in endometrial cancer, showing a 62.5% response rate in selected patients. The company is advancing ACR-2316 ahead of schedule and making progress with its AP3 Interactome. A webcast with Dr. Ramez N. Eskander is scheduled.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:46 am

BDTX

Black Diamond Therapeutics presented real-world data on NSCLC patients with non-classical EGFR mutations at ESMO 2024. The study analyzed 3,276 cases, showing most patients receive frontline chemotherapy, with others treated with osimertinib or afatinib. The short treatment discontinuation time highlights an unmet need.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:40 am

NCNA

NuCana presented final data from its Phase 2 Nutide:701 study at the ESMO Congress. The study focused on NUC-7738 in combination with Pembrolizumab for patients with metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:38 am

INCY

Incyte has unveiled promising results for its CDK2 inhibitor, INCB123667, in treating advanced solid tumors, including ovarian cancer. The data supports a pivotal trial in ovarian cancer set for 2025 and plans for combination treatments.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:58 am

EL

Estée Lauder has advised its stockholders to reject TRC Capital's unsolicited mini-tender offer to purchase 1,500,000 shares at $83.65 per share, which is below the current market price. The company emphasizes that TRC's offer is not endorsed and highlights the risks associated with mini-tender offers.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:47 am